Actively Recruiting

Age: 18Years +
All Genders
NCT06500728

Visual Involvement in Giant Cell Arteritis

Led by ASST Fatebenefratelli Sacco · Updated on 2024-07-15

762

Participants Needed

1

Research Sites

309 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This observational study aims to enhance the description of the different ways Giant Cell Arteritis (GCA) affects vision. The latest technology and knowledge are used to improve how we diagnose and predict patient outcomes. GCA is the most frequent vasculitis, an inflammation of vessels, in older adults. It involves large and medium-sized arteries and causes ischemic alterations such as stroke and blindness, through damage of extracranial arteries. The primary objective is to compare the frequency of the various ocular findings between the main alterations of arteritic and non-arteritic aetiology, such as Arteritic Anterior Ischemic Optic Neuropathy (A-AION) Vs. Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) or Central Retinal Artery Occlusion (CRAO) from GCA Vs. from other causes, through a comprehensive clinical and instrumental evaluation.

CONDITIONS

Official Title

Visual Involvement in Giant Cell Arteritis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients older than 18 years with clinically suspected or confirmed Giant Cell Arteritis (GCA)
  • Newly found visual involvement suspected or confirmed to be related to vasculitis
  • Ability to provide valid consent to participate in the study
  • Patients older than 18 years able to provide valid consent
  • Newly diagnosed acute visual impairment with GCA-like features but without vasculitis-related cause
Not Eligible

You will not qualify if you...

  • Existing eye diseases that could affect best visual acuity or alter eye examination findings
  • Active infections including viral, bacterial, fungal, or parasitic infections involving the eyes or surrounding areas
  • Active or latent tuberculosis treated for less than 4 weeks
  • HIV, hepatitis B, or hepatitis C infections affecting the eyes or orbital cavities
  • Systemic inflammatory diseases not caused by GCA (unless in treatment-free remission)
  • Any other condition deemed by investigators to prevent safe participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

ASST Fatebenefratelli-Sacco

Milan, Lombardy, Italy, 20157

Actively Recruiting

Loading map...

Research Team

E

Enrico Tombetti, Prof.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here